The Proteomics Core offers UCCC investigators access to analytical capabilities and the expertise to perform high-quality proteomic studies. The proteome is defined as the expressed protein complement of a fluid, cell, organ or organism. It is both time and region specific. Proteomics is the exercise of determining the proteome. The Proteomics Core assists with the identification of therapeutic targets, the elaboration of underlying mechanisms, and the identification of markers of cancer and anti-cancer therapies. Methods for protein and peptide isolation, separations, quantification, identification and bioinformatics analysis, together with expert guidance in study design, are integrated into the service offered by the Core. The Core has access to several analytical technologies thereby allowing investigators to adopt multiple strategies and to independently verify their findings. The Core also provides training in proteomics analysis and experimental design. Dr. Mark W. Duncan serves as Core Director and Dr. Kirk Hansen is the Manager at the main University of Colorado Denver Health Sciences facility and Katheryn Resing is the Director and Manager of the satellite facility at University of Colorado Boulder. Over the previous granting period the Proteomics Core Facilities were utilized by 25 Cancer Center members representing 7 out of 8 Cancer Center programs. Projects in the Core have centered on the qualitative and quantitative analysis of proteins and their isoforms in several cancers, including those of the lung, skin, thyroid and prostate. Additional mechanistic studies have also been undertaken. After review by the Oversight Committee and the Executive Committee the Core was restructured with the recruitment of Kirk Hansen as Core manager, and the adoption of a satellite facility housed on the Boulder campus. The last of these increases our capacity and adds special expertise in the characterization of post translational modification. The expansion of the facilities and personnel at the two sites has allowed for the institution of a number of new projects especially those evaluating new biomarkers in lung, breast, prostate and thyroid cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-25S2
Application #
8710584
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$961
Indirect Cost
$339
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338
Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12
Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38
Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6
Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110
Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322
Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7
Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74

Showing the most recent 10 out of 1302 publications